Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

Eris Lifesciences Limited's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.586468
debtToEquity 68.185000
earningsGrowth 0.191000
revenueGrowth 0.109000
grossMargins 0.739070
operatingMargins 0.263790
trailingEps 31.550000
forwardEps 50.491850

ERIS's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
ERIS's positive earnings and revenue growth indicate that the company is on track to expand its business. This growth suggests a strong financial outlook, with increasing profits and sales positioning ERIS for continued success in the market.
ERIS's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.
Eris Lifesciences Limited's forward EPS surpasses its trailing EPS, indicating that the company is expected to be more profitable in the current financial year. This reflects growing confidence in Eris Lifesciences Limited's earnings potential, suggesting stronger financial performance compared to the previous year.

Price projections:

Price projections for ERIS
Price projections for ERIS

The current valuation of Eris Lifesciences Limited, compared to projections, does not highlight any specific risks or opportunities. This stable scenario may lead investors to adopt a wait-and-see approach as they monitor future developments for potential shifts in the market.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


Recent analysis shows a strong buy bias for ERIS, encouraging investors to view it as a solid investment option. The positive sentiment surrounding ERIS suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.